ABBV vs MRVL: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Marvell Technology, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Marvell Technology, Inc. · Technology
$133.37
+25.2% upside to fair value
High Conviction
Grade B
QuantHub Verdict
MRVL has more upside to fair value
(+25.2%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MRVL |
| Current Price |
$208.05 |
$133.37 |
| Fair Value Estimate |
$217.50 |
$167.00 |
| Upside to Fair Value |
+4.5%
|
+25.2%
|
| Market Cap |
$367.9B |
$116.6B |
| Forward P/E |
14.9x
|
42.4x
|
| EV / EBITDA |
16.7x
|
—
|
| Price / Sales |
6.1x
|
14.2x
|
| Price / FCF |
20.9x
|
83.7x
|
| Revenue Growth YoY |
+8.6%
|
+7.0%
|
| Gross Margin |
83.7%
|
50.1%
|
| Operating Margin |
34.7%
|
16.3%
|
| Return on Equity |
-129.24%
|
19.4%
|
| Dividend Yield |
3.2% |
— |
| FCF Yield |
4.78%
|
1.2%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Marvell Technology designs semiconductors for data infrastructure, including storage, networking, connectivity for AI, cloud, 5G, and automotive; the business excels with a dominant Data Center segment driving 42% FY2026 revenue growth to $8.2B amid AI demand, strong leadership under long-tenured CEO Matt Murphy, and robust 50% gross margins, though offset by earnings decline and non-Data Center …
Accumulation Zones
| Metric |
ABBV |
MRVL |
| Zone Low |
$163.13 |
$125.00 |
| Zone High |
$184.88 |
$142.00 |
| In Buy Zone? |
No
|
Yes
|